Strong Expression of Cancertestis Antigens CTAG1B and MAGEA3 Is Correlated with Unfavourable Histopathological Features and MAGEA3 Is Associated with Worse Progression-Free Survival in Urothelial Bladder Cancer
Uro-Oncology
RECOMMENDED
Related content
Overactive BladderUro-Oncology
High neutrophil-to-lymphocyte ratio predicts worse overall survival in patients with advanced/metastatic urothelial bladder cancer
Int J Urol.
Tan YG, Eu EWC, Huang HH, Lau WKO
doi: 10.1111/iju.13480.
Further Publications Urology
Identification of a locus near ULK1 associated with progression-free survival in ovarian cancer
Cancer Epidemiol Biomarkers Prev
Quinn MC, McCue K, Shi W, Johnatty SE, Beesley J, Civitarese A, O'Mara TA, Glubb DM, Tyrer JP, Armasu SM, Ong JS, Gharahkhani P, Lu Y, Gao B, Patch AM, Fasching PA, Beckmann MW, Lambrechts D, Vergote I, Velez Edwards D, Beeghly-Fadiel A, Benitez J, Garcia MJ, Goodman MT, Dork T, Durst M, Modugno F, Moysich K, du Bois A, Pfisterer J, Bauman K, Karlan BY, Lester J, Cunningham JM, Larson MC, McCauley BM, Kjaer SK, Jensen A, Høgdall CK, Høgdall E, Schildkraut JM, Riggan MJ, Berchuck A, Cramer DW, Terry KL, Borge L, Webb PM, Friedlander M, Pejovic T, Moffit M, Glasspool R, May T, Ene GE, Huntsman DG, Woo M, Carney ME, Hinsley S, Heitz F, Fereday S, Kennedy CJ, Edwards SL, Winham SJ, DeFazio A, Pharoah PDP, Goode EL, MacGregor S, Chenevix-Trench G
doi: 10.1158/1055-9965.EPI-20-1817
Overactive BladderUro-Oncology
Pure but Not Mixed Histologic Variants Are Associated With Poor Survival at Radical Cystectomy in Bladder Cancer Patients
Clin Genitourin Cancer.
Moschini M, Shariat SF, Lucianò R, D'Andrea D, Foerster B, Abufaraj M, Bandini M, Dell'Oglio P, Damiano R, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A
doi: 10.1016/j.clgc.2016.12.006.
Overactive BladderUro-Oncology
Detection and Clinical Significance of Circulating Tumor Cells in Patients Undergoing Radical Cystectomy for Urothelial Bladder Cancer
Clin Genitourin Cancer.
Pagliarulo V, Ancona P, Petitti T, Salerno A, Spadavecchia R, Di Stasi S, Cormio L, Maurizio B, Carrieri G, Ditonno P
doi: 10.1016/j.clgc.2016.11.005.
Overactive BladderUro-Oncology
An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer
World J Urol.
Ferro M, Vartolomei MD, Russo GI, Cantiello F, Farhan ARA, Terracciano D, Cimmino A, Di Stasi S, Musi G, Hurle R, Serretta V, Busetto GM, De Berardinis E, Cioffi A, Perdonà S, Borghesi M, Schiavina R, Cozzi G, Almeida GL, Bove P, Lima E, Grimaldi G, Matei DV, Crisan N, Muto M, Verze P, Battaglia M, Guazzoni G, Autorino R, Morgia G, Damiano R, de Cobelli O, Shariat S, Mirone V, Lucarelli G
doi: 10.1007/s00345-018-2397-1.
Overactive BladderUro-Oncology
Chronic kidney disease as a risk factor for recurrence and progression in patients with primary non-muscle-invasive bladder cancer
Int J Urol.
Kobatake K, Hayashi T, Black PC, Goto K, Sentani K, Kaneko M, Yasui W, Mita K, Teishima J, Matsubara A
doi: 10.1111/iju.13389.
Overactive BladderUro-Oncology
Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer
Mayo Clin Proc.
Giridhar KV, Kohli M
doi: 10.1016/
HPV and Gynecologic Cancer
Cross-cancer genome-wide association study of endometrial cancer and epithelial ovarian cancer identifies genetic risk regions associated with risk of both cancers
Cancer Epidemiol Biomarkers Prev.
Glubb DM, Thompson DJ, Aben KK, Alsulimani A, Amant F, Annibali D, Attia J, Barricarte A, Beckmann MW, Berchuck A, Bermisheva M, Bernardini MQ, Bischof K, Bjørge L, Bodelon C, Brand AH, Brenton JD, Brinton LA, Bruinsma F, Buchanan DD, Burghaus S, Bützow R, Cai H, Carney ME, Chanock SJ, Chen C, Chen X, Chen Z, Cook LS, Cunningham JM, De Vivo I, DeFazio A, Doherty JA, Dork T, du Bois A, Dunning AM, Durst M, Edwards T, Edwards RP, Ekici AB, Ewing A, Fasching PA, Ferguson S, Flanagan JM, Fostira F, Fountzilas G, Friedenreich CM, Gao B, Gaudet MM, Gawełko J, Gentry-Maharaj A, Giles GG, Glasspool R, Goodman MT, Gronwald J, Harris HR, Harter P, Hein A, Heitz F, Hildebrandt MAT, Hillemanns P, Høgdall E, Høgdall CK, Holliday EG, Huntsman DG, Huzarski T, Jakubowska A, Jensen A, Jones ME, Karlan BY, Karnezis A, Kelley JL, Khusnutdinova E, Killeen JL, Kjaer SK, Klapdor R, Köbel M, Konopka B, Konstantopoulou I, Kopperud RK, Koti M, Kraft P, Kupryjanczyk J, Lambrechts D, Larson MC, Le Marchand L, Lele S, Lester J, Li AJ, Liang D, Liebrich C, Lipworth L, Lissowska J, Lu L, Lu KH, Macciotta A, Mattiello A, May T, McAlpine JN, McGuire V, McNeish IA, Menon U, Modugno F, Moysich KB, Nevanlinna H, Odunsi K, Olsson H, Orsulic S, Osorio A, Palli D, Park-Simon TW, Pearce CL, Pejovic T, Permuth JB, Podgorska A, Ramus SJ, Rebbeck TR, Riggan MJ, Risch HA, Rothstein JH, Runnebaum IB, Scott RJ, Sellers TA, Senz J, Setiawan VW, Siddiqui N, Sieh W, Spiewankiewicz B, Sutphen R, Swerdlow AJ, Szafron LM, Teo SH, Thompson PJ, Thomsen LCV, Titus L, Tone A, Tumino R, Turman C, Vanderstichele A, Velez Edwards D, Vergote I, Vierkant RA, Wang Z, Wang-Gohrke S, Webb PM, White E, Whittemore AS, Winham SJ, Wu X, Wu AH, Yannoukakos D, Spurdle AB, O'Mara TA
doi: 10.1158/1055-9965.EPI-20-0739.
Overactive BladderUro-Oncology
Propensity matched comparative analysis of survival following chemoradiation or radical cystectomy for muscle-invasive bladder cancer
BJU Int
Ritch CR, Balise R, Prakash NS, Alonzo D, Almengo K, Alameddine M, Venkatramani V, Punnen S, Parekh DJ, Gonzalgo ML
doi: 10.1111/bju.14109.